Jillian B. Thomsen net worth and biography

Jillian Thomsen Biography and Net Worth

Jillian B. Thomsen was appointed Chief Accounting Officer in April 2008. She has over 20 years of financial reporting and accounting experience. In her current role, Ms. Thomsen oversees accounting, financial reporting, planning & analysis, Sarbanes-Oxley compliance, treasury, and tax functions at the company. Previously, she served as Vice President, Finance and Controller of Nektar.

Prior to joining Nektar in 2006, Ms. Thomsen was Deputy Controller of Calpine Corporation from September 2002 to February 2006. From December 1990 to May 2002, Ms. Thomsen performed various roles with Arthur Andersen starting as a staff accountant and concluding as a senior manager.

Ms. Thomsen holds a Masters of Accountancy degree from the University of Denver and a B.A. in Business Economics from Colorado College.

What is Jillian B. Thomsen's net worth?: The estimated net worth of Jillian B. Thomsen is at least $1.21 million as of February 16th, 2023. Ms. Thomsen owns 20,899 shares of Nektar Therapeutics stock worth more than $1,205,663 as of December 4th. This net worth approximation does not reflect any other investments that Ms. Thomsen may own. Learn More about Jillian B. Thomsen's net worth.
How do I contact Jillian B. Thomsen?: The corporate mailing address for Ms. Thomsen and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at [email protected]. Learn More on Jillian B. Thomsen's contact information.
Has Jillian B. Thomsen been buying or selling shares of Nektar Therapeutics?: Jillian B. Thomsen has not been actively trading shares of Nektar Therapeutics over the course of the past ninety days. Most recently, Jillian B. Thomsen sold 684 shares of the business's stock in a transaction on Thursday, February 16th. The shares were sold at an average price of $45.00, for a transaction totalling $30,780.00. Following the completion of the sale, the chief financial officer now directly owns 20,899 shares of the company's stock, valued at $940,455. Learn More on Jillian B. Thomsen's trading history.
Who are Nektar Therapeutics' active insiders?: Nektar Therapeutics' insider roster includes Robert Chess (Director), Myriam Curet (Director), Gil Labrucherie (CFO), John Northcott (SVP), Howard Robin (CEO), Jillian Thomsen (CAO), Roy Whitfield (Director), Mark Wilson (SVP), and Jonathan Zalevsky (Insider). Learn More on Nektar Therapeutics' active insiders.
Are insiders buying or selling shares of Nektar Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 43,135 shares worth more than $1,344,931.62. The most recent insider tranaction occured on November, 25th when insider Jonathan Zalevsky sold 1,157 shares worth more than $62,801.96. Insiders at Nektar Therapeutics own 5.3% of the company. Learn More about insider trades at Nektar Therapeutics.
Information on this page was last updated on 11/25/2025.

Jillian B. Thomsen Insider Trading History at Nektar Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/16/2023	Sell	684	$45.00	$30,780.00	20,899
11/16/2022	Sell	739	$53.55	$39,573.45	21,584
8/16/2022	Sell	133	$71.40	$9,496.20	22,323
5/16/2022	Sell	389	$59.25	$23,048.25	11,361
2/16/2022	Sell	157	$164.25	$25,787.25
8/16/2021	Sell	889	$207.45	$184,423.05
5/17/2021	Sell	892	$274.50	$244,854.00
1/28/2021	Sell	5,000	$279.30	$1,396,500.00
8/17/2020	Sell	91	$295.05	$26,849.55
2/18/2020	Sell	92	$335.25	$30,843.00
2/6/2020	Sell	2,500	$341.70	$854,250.00
11/18/2019	Sell	180	$269.55	$48,519.00
8/16/2019	Sell	120	$272.25	$32,670.00	6,177
5/16/2019	Sell	128	$470.55	$60,230.40
2/19/2019	Sell	120	$635.85	$76,302.00
2/4/2019	Sell	1,074	$632.40	$679,197.60
11/16/2018	Sell	267	$573.75	$153,191.25
5/16/2018	Sell	238	$1,250.85	$297,702.30
4/16/2018	Sell	925	$1,521.90	$1,407,757.50
2/16/2018	Sell	169	$1,244.10	$210,252.90
8/16/2017	Sell	176	$289.80	$51,004.80
3/20/2017	Sell	7,500	$295.35	$2,215,125.00
7/11/2016	Sell	6,666	$226.35	$1,508,849.10	7,120
5/17/2016	Sell	48	$203.70	$9,777.60	468
2/17/2016	Sell	47	$178.80	$8,403.60	343
2/10/2016	Sell	1,000	$172.35	$172,350.00	266
1/19/2016	Sell	1,000	$211.80	$211,800.00	266
12/3/2015	Sell	1,000	$238.05	$238,050.00	266
11/11/2015	Sell	1,000	$202.80	$202,800.00	233
10/6/2015	Sell	1,000	$164.85	$164,850.00	233
9/23/2015	Sell	666	$195.60	$130,269.60	233
12/22/2014	Sell	333	$233.40	$77,722.20

Jillian B. Thomsen Buying and Selling Activity at Nektar Therapeutics

Nektar Therapeutics Company Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Today's Range

Now: $57.69

$54.75

$57.86

50 Day Range

MA: $58.84

$53.95

$65.69

2 Week Range

Now: $57.69

$6.45

$66.92

Volume

475,955 shs

Average Volume

649,746 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27